|1.||Krawiecka, Mariola: 1 article (05/2013)|
|2.||Chilmonczyk, Zdzisław: 1 article (05/2013)|
|3.||Kossakowski, Jerzy: 1 article (05/2013)|
|4.||Kuran, Bozena: 1 article (05/2013)|
|5.||Koronkiewicz, Mirosława: 1 article (05/2013)|
|6.||Fujii, Norihiko: 1 article (01/2013)|
|7.||Fujii, Noriko: 1 article (01/2013)|
|8.||Aki, Kenzo: 1 article (01/2013)|
|9.||Kocharov, Sergey L: 1 article (06/2012)|
|10.||Kominek, Mateusz: 1 article (06/2012)|
|1.||Absence Epilepsy (Absence Seizure)
01/01/1991 - "A subset where it is more frequently seen are in adults with persistent absence seizures when the latter become finally controlled by succinimide therapy. "
06/03/1960 - "[The therapy of retropulsive petit mal epilepsy (pyknolepsy) with methylethyl succinimide]."
12/11/1958 - "[A new succinimide in the treatment of petit mal epilepsy]."
05/01/1956 - "Evaluation of N-methyl-a, a-methylphenyl succinimide in the treatment of petit mal epilepsy."
08/01/1951 - "Use of methylphenyl-succinimide in treatment of petit mal epilepsy."
09/01/1987 - "A succinimide was required as a second antiepileptic drug in 3 patients to achieve seizure control. "
06/01/2012 - "Therefore, the aim of this study was to determine the effects of N-hydroxymethyl-p-isopropoxyphenyl-succinimide (HMIPPS) on the protective action of four classical antiepileptic drugs (carbamazepine, phenobarbital, phenytoin and valproate) in the maximal electroshock-induced seizure test in mice. "
01/01/1969 - "[On the possibility of using the concept of pathometamorphosis (pathomorphosis) in the understanding the clinical picture in various forms of epilepsy in connection with succinimide therapy]."
03/23/1963 - "[On the treatment of petitmal epilepsy with alpha-methyl-alpha-ethyl-succinimide in form of a syrup]."
03/01/1961 - "Treatment of epilepsy with alpha-ethyl-alpha-methyl-succinimide (P.M. "
04/01/1960 - "[Experiences with PM 671 (alpha-ethyl-alpha-methyl-succinimide) in the treatment of epilepsy in children]."
04/18/1959 - "[Preliminary report on experiences with the succinimide celonthin in the treatment of epilepsy]."
|4.||Dehydration (Water Stress)
09/01/1996 - "alpha-beta Isomerization at the 33-position was expected in view of the previous isolation of a potential precursor (Asp33-Gly34-anhydro-hirudin (Ic)), i.e., a succinimide-type dehydration product liable to undergo facile hydrolysis with ring opening, yielding beta- (along with alpha-) aspartates. "
12/01/1993 - "Two congeners Q4 and Q5 inferred in earlier analyses to be cyclic succinimide-type dehydration products of recombinant hirudin (variant 1) were structurally fully characterized. "
12/01/1993 - "Characterization of succinimide-type dehydration products of recombinant hirudin variant 1 by electrospray tandem mass spectrometry."
07/01/2003 - "Formation of betalinked Asp-Xaa peptide bonds--isoaspartyl (isoAsp) sites--arise in proteins via succinimide-linked deamidation of asparagine or dehydration of aspartate, reactions which represent a major source of spontaneous protein damage under physiological conditions. "
09/01/1988 - "We both discuss the theoretical background and provide practical procedures for each of the following steps: cell culture on Formvar-coated gold grids; prefixation with aldehydes or protein crosslinking reagents (homobifunctional N-hydroxy-succinimide esters); extraction with Triton X-100 or Brij 58 detergent in microtubule stabilizing buffer; postfixation in formaldehyde and glutaraldehyde; dehydration; critical point and freeze drying; sputter coating with 1-2 nm of platinum or tungsten; and examination by SEM and both normal and inverted contrast STEM. "
|2.||Anticonvulsants (Antiepileptic Drugs)
|3.||Valproic Acid (Valproate, Semisodium)
|7.||Proteins (Proteins, Gene)